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Thrombolysis May Improve Outcomes
for Post-Catheterization Cerebrovascular Accidents
Ischemic strokes occur after approximately 1% of cardiac catheterizations, yet thereis little known about the best treatment algorithms.Khatri and colleagues compared
the clinical outcomes of 66 cases treated either with or without thrombolysis. Twelve
(18%) were treated with thrombolysis, either intravenous or intra-arterial, using
recombinant tissue plasminogen activator. Improvement in stroke symptoms, as mea-
sured by the change inNational Institutes of Health stroke scale score from baseline to
24 h, was greater in treated versus nontreated cases. There were no significant differ-
ences in bleeding events. This retrospective study suggests that thrombolysis may
improve outcomes for post-catheterization strokes. Thrombolysis should be consid-
ered in those with significant symptoms, even those who are already anticoagulated.
See pages 906 and 912.
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Coronary Heart Disease
Lp-PLA2 Levels Improve Cardiac Risk Prediction in Older Adults
Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyzes oxidized phos-pholipids, yielding proinflammatory and proatherogenic products. Some, but not
all, studies have found levels of Lp-PLA2 tobe an independent predictor of cardiac risk.
Daniels and colleagues analyzed serum samples collected nearly 20 years ago from
participants in the Rancho Bernardo Study, which enrolled over 1,000 men and
women with a median age of 72 years and no known coronary heart disease (CHD).
After a mean follow-up of 16 years, 228 participants had incident CHD events.
Lp-PLA2 levels in the second, third, and fourth quartiles predicted an increased risk of
CHD compared with the lowest quartile (hazard ratios 1.66, 1.80, and 1.89, respec-
tively). This association persisted after adjusting forC-reactive protein and otherCHD
risk factors. These results show that Lp-PLA2 levels predictCHDevents in older adults
independently of other known CHD risk factors. See page 913. See figure.
Heart Rhythm Disorders
Heart Rate Variability is an Important Risk Modifier in LQTS
Some long QT syndrome (LQTS) patients experience life-threatening cardiacarrhythmias, whereas others remain asymptomatic. Those with LQT1 mutations
typically experience arrythmias during stressful situations. Shwartz and colleagues
studied markers of sympathetic activation and cardiac responsiveness in patients with
LQT1 mutations who had or had not experienced a significant arrythmia. The mean
heart rate was lower among asymptomatic patients; baroreflex sensitivity (BRS) was
also lower among asymptomatic than symptomatic mutation carriers. Lower resting
heart rate and “relatively low” BRS appear to be protective factors in certain LQT1
carriers; this may occur because a blunted autonomic response prevents rapid changes
in heart rate, which may be arrhythmogenic when delayed rectifier current (slow) is
reduced. See pages 920 and 930.
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Preclinical Research
Pre-Treating Stem Cells with GFs
Improves Cardiac Differentiation and Integration
The goal of this study was to investigate several putative growth factors (GFs) fortheir effect on mesenchymal stem cells (MSCs). Mesenchymal stem cells ob-
tained from the bonemarrowof rats were pre-treatedwith fibroblastGF-2, insulin-like
GF-1, and bone morphogenetic protein 2. The priming of MSCs with this combina-
tion enhanced the commitment of MSCs to cardiomyocyte (CMC) lineage when
cocultured with CMCs. Pre-treated cells also formed more gap junctions with neigh-
boring CMCs, which helped to prevent apoptosis under hypoxic conditions and
seemed to reduce the tendency towards lethal arrythmias. Treatment of MSCs with a
combination of GFs may increase the therapeutic efficacy of MSC transplantation to
infarcted myocardium. See page 933. See figure.
